Isoliquiritigenin Attenuates Monocrotaline-Induced Pulmonary Hypertension via Inhibition of the Inflammatory Response and PASMCs Proliferation

<p>Effects of ISL on hypoxia-induced PASMCs proliferation. Values are means ± SEM (<i>n</i> = 5). <sup>#</sup><i> p</i> &lt; 0.05, <sup>##</sup><i> p</i> &lt; 0.01, and <sup>###</sup><i> p</i> &lt; 0.001, compared with normoxia group; <svg height="12.2304pt" id="M22" style="vertical-align:-0.04990005pt" version="1.1" viewbox="-0.0498162 -12.1805 4.98213 12.2304" width="4.98213pt" xmlns="http://www.w3.org/2000/svg"><g transform="matrix(.0091,0,0,-0.0091,0,-5.741)"><path d="M263 363V584C343 572 363 521 380 464L408 470C399 526 392 562 387 596C376 598 367 601 353 604C328 612 296 617 263 617V693H228V615C122 603 67 532 67 453C67 376 123 329 193 300L228 284V41C132 52 93 131 75 189L45 181C54 130 66 71 73 50C113 24 170 9 228 9V-76H263V11C370 24 434 90 434 185C434 275 367 325 292 352L263 363ZM228 376C171 398 136 431 136 484C136 530 164 578 228 584V376ZM263 272L275 267C345 236 359 196 359 150C359 96 325 50 263 42V272Z"></path></g></svg><i> p</i> &lt; 0.05, <svg height="12.2304pt" id="M23" style="vertical-align:-0.04990005pt" version="1.1" viewbox="-0.0498162 -12.1805 9.36649 12.2304" width="9.36649pt" xmlns="http://www.w3.org/2000/svg"><g transform="matrix(.0091,0,0,-0.0091,0,-5.741)"><path d="M263 363V584C343 572 363 521 380 464L408 470C399 526 392 562 387 596C376 598 367 601 353 604C328 612 296 617 263 617V693H228V615C122 603 67 532 67 453C67 376 123 329 193 300L228 284V41C132 52 93 131 75 189L45 181C54 130 66 71 73 50C113 24 170 9 228 9V-76H263V11C370 24 434 90 434 185C434 275 367 325 292 352L263 363ZM228 376C171 398 136 431 136 484C136 530 164 578 228 584V376ZM263 272L275 267C345 236 359 196 359 150C359 96 325 50 263 42V272Z"></path></g><g transform="matrix(.0091,0,0,-0.0091,4.368,-5.741)"><path d="M263 363V584C343 572 363 521 380 464L408 470C399 526 392 562 387 596C376 598 367 601 353 604C328 612 296 617 263 617V693H228V615C122 603 67 532 67 453C67 376 123 329 193 300L228 284V41C132 52 93 131 75 189L45 181C54 130 66 71 73 50C113 24 170 9 228 9V-76H263V11C370 24 434 90 434 185C434 275 367 325 292 352L263 363ZM228 376C171 398 136 431 136 484C136 530 164 578 228 584V376ZM263 272L275 267C345 236 359 196 359 150C359 96 325 50 263 42V272Z"></path></g></svg><i> p</i> &lt; 0.01, and <svg height="12.2304pt" id="M24" style="vertical-align:-0.04990005pt" version="1.1" viewbox="-0.0498162 -12.1805 13.7508 12.2304" width="13.7508pt" xmlns="http://www.w3.org/2000/svg"><g transform="matrix(.0091,0,0,-0.0091,0,-5.741)"><path d="M263 363V584C343 572 363 521 380 464L408 470C399 526 392 562 387 596C376 598 367 601 353 604C328 612 296 617 263 617V693H228V615C122 603 67 532 67 453C67 376 123 329 193 300L228 284V41C132 52 93 131 75 189L45 181C54 130 66 71 73 50C113 24 170 9 228 9V-76H263V11C370 24 434 90 434 185C434 275 367 325 292 352L263 363ZM228 376C171 398 136 431 136 484C136 530 164 578 228 584V376ZM263 272L275 267C345 236 359 196 359 150C359 96 325 50 263 42V272Z"></path></g><g transform="matrix(.0091,0,0,-0.0091,4.368,-5.741)"><path d="M263 363V584C343 572 363 521 380 464L408 470C399 526 392 562 387 596C376 598 367 601 353 604C328 612 296 617 263 617V693H228V615C122 603 67 532 67 453C67 376 123 329 193 300L228 284V41C132 52 93 131 75 189L45 181C54 130 66 71 73 50C113 24 170 9 228 9V-76H263V11C370 24 434 90 434 185C434 275 367 325 292 352L263 363ZM228 376C171 398 136 431 136 484C136 530 164 578 228 584V376ZM263 272L275 267C345 236 359 196 359 150C359 96 325 50 263 42V272Z"></path></g><g transform="matrix(.0091,0,0,-0.0091,8.736,-5.741)"><path d="M263 363V584C343 572 363 521 380 464L408 470C399 526 392 562 387 596C376 598 367 601 353 604C328 612 296 617 263 617V693H228V615C122 603 67 532 67 453C67 376 123 329 193 300L228 284V41C132 52 93 131 75 189L45 181C54 130 66 71 73 50C113 24 170 9 228 9V-76H263V11C370 24 434 90 434 185C434 275 367 325 292 352L263 363ZM228 376C171 398 136 431 136 484C136 530 164 578 228 584V376ZM263 272L275 267C345 236 359 196 359 150C359 96 325 50 263 42V272Z"></path></g></svg><i> p</i> &lt; 0.001, compared with hypoxia group; <sup>@</sup><i> p</i> &lt; 0.05, compared with Hypoxia+ISL 100 <i>μ</i>M group.</p>

Evidence-Based Complementary and Alternative Medicine

fig7

Figure 7

Figure 7: Isoliquiritigenin Attenuates Monocrotaline-Induced Pulmonary Hypertension via Inhibition of the Inflammatory Response and PASMCs Proliferation 

Figure 7 | Isoliquiritigenin Attenuates Monocrotaline-Induced Pulmonary Hypertension via Inhibition of the Inflammatory Response and PASMCs Proliferation 